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Purpose: To investigate the short‐term efficacy of topical immunosuppressive agents on the survival of 
cultivated allo‐conjunctival equivalents. 
Methods:  Twenty‐five eyes of New Zealand white rabbits were included. Temporal conjunctivae were 
trephined to a diameter of 7.5 mm, and then cultured allo‐conjunctival epithelial cells on amniotic membrane 
were transplanted onto them. Various immunosuppressants including steroid, cyclosporine, and rapamycin 
were applied topically four times a day for a week. Epithelial defects and graft edema were graded daily. 
Numbers of inflammatory cells were measured in H&E. PKH26 and cytokeratin 4 and 7 were 
immunostained.
Results: Earlier epithelialization was observed in 1% steroid‐treated eyes and defects persisted significantly 
in 0.5% CsA applied eyes. In histology, PKH26 positive cells considered as donor cells were only found in 
1% steroid or 0.01% rapamycin applied eyes. 1% steroid‐ or 0.01% rapamycin‐applied eyes both showed 
positive staining for keratin‐4 and ‐7. Inflammatory cells were less found in 1% steroid or 0.01% rapamycin 
treated eyes.
Conclusions: Topical steroid or rapamycin can help to suppress acute inflammation and enhance the acute 
survival of transplanted conjunctival cells.
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Conjunctival transplantation in conjunctiva depleting diseases 
has been described for several decades.
1‐4 However, most 
conjunctival allografts have failed because they are rejected 
more easily than corneal allografts. The immunosuppressive 
agents have been used in order to reduce the rejections. 
Although systemic immunosuppressive agents have multiple 
systemic side effects,
5 systemic immunosuppression is known 
to be needed for the survival and maintenance of allo‐
conjunctival grafts.
6 The mechanisms of immunosuppressive 
agents are different from each other. Steroid and 
rapamycin inhibit various types of inflammatory cells and 
neovascularization.
7‐9 Cyclosporin has been known that it 
inhibits T and/or B cell and can retard the corneal 
neovascularization but is ineffective in blocking vessel 
growth in the subcutaneous disc angiogenesis system.
10
Recently, a study reported that the cultivation of cells 
reduced antigenicity,
11 and the transplantation of cultivated 
allo‐conjunctival cells has been attempted. We thought that 
these reduced antigenicity may allow the systemic 
immunosuppressive agents to be unnecessary or little 
necessary with topical application of immunosuppressive 
agents.
The penetrations of topical immunosuppressants including Kor J Ophthalmol Vol.22, No.2, 2008
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Fig. 1. Temporal conjunctivae was trephined to a diameter of 
7.5 mm, and cultivated conjunctival equivalent or an allo‐
conjunctival graft was transplanted. 
cyclosporine, FK506, and rapamycin have been investigated 
in animal models, which showed variable results across the 
studies.
12‐20
We hypothesized that topical immunosuppressants may 
affect the survivals of conjunctival and corneal grafts 
differently, even if deep penetration by drugs may not be 
achieved. Therefore, we investigated the efficacies of various 
topical immunosuppressive agents on the survival of 
transplanted cultivated allo‐conjunctival cells (conjunctival 
equivalents) in this study.
Materials and Methods
Animals 
All procedures were performed according to the ARVO 
Statement for the use of Animals in Ophthalmic and Vision 
Research. New Zealand white rabbits of both sexes aged 
between 4 and 6 months were used in all experiments. 
Rabbits were sacrificed by an intramuscular injection of 50 
mg xylazine hydrochloride and 50 mg ketamine hydrochloride 
followed by an intravenous overdose of sodium pentobarbital. 
Twenty‐five eyes were allocated to five groups according to 
treatment modality. 
Conjunctival equivalents construction
We cultured rabbit conjunctival epithelial cells using a 
previously described culture system for conjunctival epithelial 
stem cells, with several modifications.
21,22 Briefly, rabbit 
conjunctival tissues were treated with 0.05% trypsin and 
0.01% ethylenediaminetetraacetic acid (EDTA) at 37℃ with 
gentle shaking (HB‐Movcst 220, Hybaid Limited, U.K). 
Suspended cells were collected every 20 minutes 4 times. 
After plating NIH3T3 feeder cells which were treated with 
4 µg/ml mitomycin C (MMC) at 37°C for 2 hr, epithelial 
cells (1.5‐1.8×10
4 cell/cm
2) were seeded onto human denuded 
amniotic membrane (AM) in culture inserts and co‐cultured 
in 5% CO2 at 37°C. The medium used consisted of SHEM 
supplemented with 10% FBS (Gibco, USA) in DMEM/F12 
(1:1) (Gibco, USA), 0.5% PS (Gibco, USA), 4 mM L‐
glutamine (Sigma, USA), 5 ng/ml EGF (Sigma, USA), 5 
µg/ml insulin (Sigma, USA), 30 ng/ml choleratoxin (Sigma, 
USA), 0.18 mM adenine (Sigma, USA), 2 nM 3.3', 5 triiodo‐
L‐thyromine sodium salt, and 0.4 µg/ml hydrocortisone. 
Epithelial cells were submerged in the medium and cultured 
for 2 weeks. All epithelial sheets on AMs were well 
maintained and showed no phenotypical differences.
Surgical Procedure
Cultivated cells on denuded AMs for 2 weeks were used 
as cultivated conjunctival equivalents. Temporal conjunctivae 
were trephined to a diameter of 7.5 mm. Cultivated conjunctival 
equivalents were transplanted to the defected conjunctival 
lesion in recipients (Fig. 1) and sutured with interrupted and 
continuous 10‐0 nylon. AMs were overlaid using 10‐0 nylon 
to help graft stability.
Treatment 
Each eye was treated four times daily with topical 
application of 1% steroid (Pred Forte
®, Allergen, USA, n=5), 
0.5% cyclosporine A (n=5), or 0.01% rapamycin (n=5) or 
with no topical treatment (controls; n=5). These represented 
the five topical treatment groups. 0.5% cyclosporine A eye 
drops was prepared with emulsifying cyclosporine A 
(Sandimun, Novatis, USA) in normal saline. Topical 
rapamycin (Sigma, USA) was mixed with phosphate buffer 
solution (PBS) and diluted to 0.01%.
Clinical Graft Evaluation
Each rabbit was examined daily under a microscope for 7 
days after conjunctival equivalent transplantation. A single 
masked observer scored each conjunctival equivalent graft 
under the microscope using scales of epithelial defect and 
graft edema. Epithelial defect was measured by fluorescein 
staining % of entire grafts, and graft edema was scored as 
0 (clear graft), 1 (mild opacity, with clearly visible episcleral 
vessels), 2 (moderate edema partly obscuring episcleral 
vessels), 3 (severe opacity totally masking episcleral vessels). 
Histology 
Animals were sacrificed 7 days after transplantation. 
Cryosections (5 µm) of the transplanted grafts per animal 
were cut and stained with H&E. To evaluate the presence 
of transplanted epithelial and goblet cells, indirect 
immunofluorescence microscopy was performed using 
monoclonal anti‐keratin 4 (Vector, USA) as a marker for 
conjunctival epithelial cell or anti‐keratin 7 (Vector) as a YJ Shin, et al. TOPICAL IMMUNOSUPPRESSANTS ON CONJUNTIVAL CELL  
125
Fig. 2. Comparison of epithelialization (A) and graft edema (B) 
between untreated and treated eyes.
Fig. 3. Number of inflammatory cells in 1% steroid, 0.5% 
cyclosporine, or 0.01% rapamycin applied eyes in the 
cultivated conjunctival equivalent transplanted group. Histogram 
data represent means±SD. * p<0.05.
marker for goblet cell. Briefly, cryostat sections (5 µm) were 
placed on gelatin‐coated slides and acetone‐fixed at room 
temperature for 15 minutes. Sections were then treated with 
proteinase K 20 µg/ml for 10 minutes and washed twice with 
PBS. To block endogenous peroxidase activity sections were 
incubated in 0.5% H2O2 for 10 minutes and then washed with 
PBS followed by PBS containing 0.3% triton X‐100 (PBST; 
3×5 minutes) and then incubated in PBS containing 1% 
serum for 30 minutes. Subsequently, sections were incubated 
at room temperature for 1 hour with primary antibody and 
then washed with PBS (2×5 minutes). The sections were then 
incubated at room temperature for 1 hour with Alexa 488 
(A11001, Molecular Probes, USA) at 2 mg/ml. After staining 
with primary antibody, sections were incubated at room 
temperature for 1 hour with appropriate secondary antibodies 
and fluorescein (FIITC)‐conjugated goat anti‐mouse IgG 
(Molecular Probes). After several washing with PBS, sections 
were coverslipped using antifading mounting. Anti‐keratin 4 
or 7 antibodies were stained on amniotic membrane without 
cells as a negative control. For cell tracing, cultured 
conjunctival epithelial cells and allo‐conjunctival cells were 
stained with 10 nM of a fluorescent dye (PKH26; Sigma, 
USA) in BSS (Alcon, USA) for 30 minutes at 37°C and then 
washed with BSS (Alcon, USA) for 30 minutes at 37°C one 
day before transplantation. Cryosections of regenerated 
conjunctiva were co‐stained with a DNA‐binding dye Hoechst 
(Sigma). The expressions of PKH26, keratin‐4, and ‐7 were 
evaluated. PKH26 positive cells were regarded as donor cells.
Statistics
Differences between control and treatment groups were 
examined using the Mann‐Whitney test. For all analyses, 
statistical significance was set at the α= 0.05 level. Data 
analysis was performed using SPSS for Windows
® ver. 12.0 
(SPSS, Chicago, USA). 
Results
Clinical results 
When compared between the control and the treatment 
group, the control group without immunosuppression showed 
decreasing conjunctival epithelial defects with time, while 
grafts in the treatment group were not epithelialized 
completely during the 7 day follow‐up period (Mann‐Whitney 
test, p=0.010 at day 7) (Fig 2A). Graft edema in the control 
group was significantly more severe on days 2 and 3 than 
in the treatment groups, while this was not significant at day 
4, 5, 6, and 7 (Mann‐Whitney test, p=0.071 at day 1, p=0.029 
at day 2, p=0.019 at day 3, p=0.097 at day 4, p=0.371 at 
day 5, p=0.488 at day 6, and p=0.336 at day 7) (Fig 2B). 
When compared among the treatment groups, epithelial 
defects tended to be decreased by steroids (Mann‐Whitney 
test,  p=0.056 in steroid treated eyes, and p=0.222 for 
rapamycin treated eyes at day 7) but defects persisted 
significantly more in 0.5% CsA applied eyes than in control 
eyes (Mann‐Whitney test, p=0.008).
Histology 
Histologic examination with H&E staining showed 
inflammatory cell infiltration was less severe in the 1% 
steroid or 0.01% rapamycin treated groups than in the control 
group (Mann‐Whitney,  p=0.000, and p=0.000 respectively) 
(Fig. 3, Table 1). Numbers of inflammatory cells were 
marked in 0.5% cyclosporine applied eyes.Kor J Ophthalmol Vol.22, No.2, 2008
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　 Number of inflammatory cells (±SD)
no treatment   267.48 (±197.39)
1% steroid  47.84 (±70.81)
0.5% cyclosporine  377.24 (±479.28)
0.01% rapamycin  63.16 (±94.48)
Table 1. Numbers of inflammatory cells in transplanted 
conjunctival equivalents 
Fig. 4. PKH26 positive cells as transplanted donor cells in untreated (A), and in 0.5% cyclosporine (B), 1% steroid (C), 0.01% 
rapamycin (D) treated eyes in the cultivated conjunctival equivalent transplanted group. Hoechst staining in steroid (E) or 0.01% 
rapamycin (F) treated eyes in the cultivated conjunctival equivalent transplanted group. Magnification; ×200. 
PKH26 staining showed no donor cells in the control 
without any immune suppressant or in 0.5% CsA treated eyes 
(Fig. 4A, B). PKH26 positive cells were found in 1% steroid, 
0.01% rapamycin applied eyes (Fig. 4C, D), and 1% steroid‐ 
or 0.01% rapamycin‐applied eyes both showed positive 
staining for keratin‐4 and ‐7 (Fig. 5A~D). We confirmed the 
cells using a DNA‐binding dye Hoechst staining (Fig. 4E, F). 
Taken together, treatment with topical steroid or rapamycin 
enhanced grafted epithelial cell survival.YJ Shin, et al. TOPICAL IMMUNOSUPPRESSANTS ON CONJUNTIVAL CELL  
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Fig. 5. Positive staining for keratin‐4 and ‐7 in 1% steroid (A and B, respectively) and 0.01% rapamycin‐applied eyes (C and D, 
respectively). Magnification; ×200.
Discussion
Perturbations of the conjunctival microenvironment may 
induce corneal damage, but it is difficult to restore the normal 
conjunctival environment after severe conjunctival damage 
resulting from inflammation or chemical insult. Allo‐
conjunctival transplantation in ocular surface disorders has 
been previously described as a trial in order to overcome 
these conditions.
2 The major problem of conjunctival 
allografts is the remarkable level of rejection.
2 Several 
immunosuppressive agents including cyclosporine A, steroids, 
and rapamycin were used systemically or topically in order 
to reduce the rejection.
12‐20 These immunosuppresseive agents 
have several side effects when they are used systemically.
12‐20
In the present study, we used human AM which has been 
described as a substitute of basement membrane.
23 It has also 
been described that epithelial cells can be adhered to AM and 
can differentiate on the AM.
23‐26 Moreover, human AM has 
been also described to display very low immunogenecity, 
suggesting that acute rejection would not occur after 
transplantation.
27,28 In addition, we cultured epithelial cells 
without the use of the murine 3T3 fibroblast in this study, 
suggesting that the donor grafts in this study were expected 
to present only alloantigens.
We evaluated the survival of donor cells after allo‐
conjunctival equivalent transplantation using PKH26 tracer 
and investigated the effect of topical immunosuppressants on 
the graft survival. PKH26 is a membrane dye that can 
facilitate tracking of the donor cells, because it is a 
fluorescent compound that is incorporated into the cell 
membrane. Therefore, PKH26 is useful for in vitro cell 
labeling, and in vitro and in vivo cell tracking applications.
29‐
33 The cells stained with PKH26 can be considered as donor 
cells or daughter cells from donor cells because we had 
stained donor cells before the transplantation.
The present study revealed earlier epithelialization and 
lower graft edema in 1% steroid‐treated eyes after the 
transplantation of cultivated allo‐conjunctival equivalents. 
Histology also showed less inflammatory cell infiltration, a 
healthy PKH26 positive cells population, and positive 
staining for cytokeratin 4 and 7 in 1% steroid or 0.01% 
rapamycin applied eyes after transplantation, suggesting that 
both might prolong the survival of grafted cells. Steroid 
suppresses an immune reaction and extends the survival of 
transplanted tissues by;
34‐36 stabilizing lysosomal membranes, 
suppressing prostaglandin synthesis, modulating the gene 
transcriptions of pro‐inflammatory cytokines (IL‐1, IL‐2, IL‐6, 
IFN‐γ and TNF‐α, via corticosteroid/glucocorticoid receptor Kor J Ophthalmol Vol.22, No.2, 2008
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complex), impairing monocyte/macrophage function, and 
decreasing the number of circulating CD4+ T cells. The 
application of topical rapamycin has been known to have a 
positive effect on immune suppression in various types of 
experimental models, e.g., on corneal allograft rejection and 
neovascularization in rats, and on endotoxin‐uveitis in 
rabbits.
34,37‐39 Rapamycin binds to FK binding protein 25 and 
inhibits mTOR (mammalian target of rapamycin), as a result, 
it blocks the cell signaling required for cell‐cycle progression 
and for the cellular proliferation of T, B, mast, and peripheral 
blood mononuclear cells, fibroblasts and others.
40,41
CsA applied eye showed more inflammatory cell infiltration 
and little PKH 26 cells. The reason why CsA had no effect 
on the survival of grafted conjunctival cells could be that 
CsA is a specific T cell suppressant. CsA binds to 
cyclophilins, and the CsA cyclophilin complex blocks the 
calmodulin/calcineurin‐induced phosphorylation of transcription 
factors (i.e., interleukin‐2) that are involved in early T‐cell 
gene expression.
34 We believe that abundant vessels in 
conjunctivae can easily recruit neutrophils and other 
mononuclear cells during the early stage, thus the nonspecific 
inhibition of early inflammatory cells seems to be required, 
as well as the inhibition of T and B cells. Therefore, T and/or 
B cell inhibition by CsA is probably not enough in 
conjunctival grafts. On the other hand, steroid or rapamycin 
have the capacity to inhibit various types of inflammatory 
cells, exerting a potent effect on conjunctival grafts. 
Meanwhile, cyclosporine is known to have epithelial 
toxicity,
42 and that is why transplanted epithelial sheet 
showed persistent epithelial defect with application of 
cyclosporin.
Generally, cultivated allo‐conjunctival equivalents in this 
study showed less inflammatory cell infiltration. This agrees 
with a previously study which found that cultivated cells had 
reduced immunogenicity.
11 However, recipient site should be 
well‐vascularized for graft survival, and the conjunctiva 
has good lymphatic drainages from subconjunctival 
lymphoid tissues.
43 As a result, immune rejection cannot 
be avoided even in cultivated cells in the absence of 
immunosuppressants. Therefore, it is remarkable that the 
topical application of 1% steroid or 0.01% rapamycin showed 
good immunosuppression and a positive effect on survival in 
cultivated allo‐conjunctival equivalents, in view of the fact 
that the conjunctiva presents a high risk area of rejection. 
We investigated the efficacy only for 7 days. It may not 
be enough time to investigate the effect on the full course 
of graft rejection. However, conjunctiva is fully vascularized 
tissue, thus early severe inflammatory responses are expected 
as well as late cell‐mediated rejection. Hence, we believe the 
evaluation of short term effect of those agents on the early 
survival of transplanted conjunctival cells would be worthy 
of notice. Further study is pending to investigate the long‐
term efficacy of topical immunosuppressants.
In conclusion, topical steroid or rapamycin were found to 
help suppress early stage inflammation, and thus, to extend 
allo‐conjunctival equivalent transplant survival, which 
suggests that these agents can be used instead of systemic 
immunosuppressants in patients that have undergone allo‐
conjunctival transplantation. 
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